$30 Billion Deal, page-2220

It's all in the Letter to Shareholders:

"Biotron is aware of shareholder interest in the progress of the clinical trials.
It is, however, imperative that the remaining laboratory work is completed
with all attention to detail and in accordance with international guidelines
for undertaking such studies.
They are complex and require careful handling in specialised facilities here in Australia and overseas. The work is in its final stage and everyone associated with the trials is focused on completing the analyses as fast as possible.
Release of headline data is expected in coming weeks."

Basically various Labs in various Countries are compiling the results,
And are making sure everything is done correctly the first time....